Cargando…

Ipidacrine (Axamon), A Reversible Cholinesterase Inhibitor, Improves Erectile Function in Male Rats With Diabetes Mellitus-Induced Erectile Dysfunction

BACKGROUND: Management of diabetes mellitus-induced erectile dysfunction (DMED) is challenging because of its insufficient responses to phosphodiesterase type 5 inhibitors. AIM: To compare the effects of ipidacrine, a reversible cholinesterase inhibitor, and sildenafil on DMED in a rat model of stre...

Descripción completa

Detalles Bibliográficos
Autores principales: Bykov, Vladimir, Gushchina, Evgenia, Morozov, Sergey, Zhuravskaya, Natalia, Kryshen, Kirill, Makarov, Valery, Matichin, Aleksandr, Zueva, Alena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847829/
https://www.ncbi.nlm.nih.gov/pubmed/35007992
http://dx.doi.org/10.1016/j.esxm.2021.100477
_version_ 1784652130828681216
author Bykov, Vladimir
Gushchina, Evgenia
Morozov, Sergey
Zhuravskaya, Natalia
Kryshen, Kirill
Makarov, Valery
Matichin, Aleksandr
Zueva, Alena
author_facet Bykov, Vladimir
Gushchina, Evgenia
Morozov, Sergey
Zhuravskaya, Natalia
Kryshen, Kirill
Makarov, Valery
Matichin, Aleksandr
Zueva, Alena
author_sort Bykov, Vladimir
collection PubMed
description BACKGROUND: Management of diabetes mellitus-induced erectile dysfunction (DMED) is challenging because of its insufficient responses to phosphodiesterase type 5 inhibitors. AIM: To compare the effects of ipidacrine, a reversible cholinesterase inhibitor, and sildenafil on DMED in a rat model of streptozotocin (STZ)-induced diabetes. METHODS: Erectile dysfunction (ED) caused by STZ-induced diabetes mellitus was modeled in adult male Wistar rats, which were randomized to 4 groups: untreated diabetic rats, sildenafil (5 mg/kg), ipidacrine (3.6 mg/kg) and ipidacrine (6.7 mg/kg). The test drug (ipidacrine), comparator (sildenafil) or control substance (1% starch solution) were administered orally for 5 days or 14 days. Erectile function was assessed by the change in the maximum intracavernous pressure (ICPmax) following cavernous nerve electrical stimulation. The mean arterial pressure (MAP) was recorded, and the ICPmax/MAP ratio was calculated. Sexual behavior, cholinesterase activity and blood testosterone level tests assessed. MAIN OUTCOME MEASURE: The quantitative value of ICPmax/MAP 14 days after the start of administration of the test drug and the comparison drug. RESULTS: Animals with STZ-induced diabetes mellitus showed a significant decrease in ICPmax and ICPmax/MAP ratio compared to the intact control group. When ipidacrine was administered to rats with DMED for 14 days, an increase in these indicators was noted. It was proved that ipidacrine at a dose of 6.7 mg/kg has noninferiority compared to sildenafil on the DMED model. Significant increase in ICPmax compared to STZ-control after electrostimulation of the cavernous nerve was recorded following administration of ipidacrine at a dose of 6.7 mg/kg (P < .05) and sildenafil at a dose 5 mg/kg (P < .05). Neither the test drug, nor the comparator were associated with increase in testosterone levels in blood; as well both drugs did not promote activation of sexual behavior. CLINICAL IMPLICATIONS: Ipidacrine may be considered as an effective therapy for DMED but needs to be verified in human investigations. STRENGTHS & LIMITATIONS: The role of ipidacrine, was firstly demonstrated in rats with DMED. However, the results were obtained in animal experiments, and will be further tested in the study of receptor interactions and the determination of cellular targets. CONCLUSION: This is the first study to show that administration of ipidacrine, the reversible cholinesterase inhibitor, improved erectile function in diabetic rats and these results may be beneficial in further studies using ipidacrine for treatment of DMED, particularly in non-responders to PDE5 inhibitors. Bykov V, Gushchina E, Morozov S, et al. Ipidacrine (Axamon), A Reversible Cholinesterase Inhibitor, Improves Erectile Function in Male Rats With Diabetes Mellitus-Induced Erectile Dysfunction. Sex Med 2022;10:100477.
format Online
Article
Text
id pubmed-8847829
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-88478292022-02-22 Ipidacrine (Axamon), A Reversible Cholinesterase Inhibitor, Improves Erectile Function in Male Rats With Diabetes Mellitus-Induced Erectile Dysfunction Bykov, Vladimir Gushchina, Evgenia Morozov, Sergey Zhuravskaya, Natalia Kryshen, Kirill Makarov, Valery Matichin, Aleksandr Zueva, Alena Sex Med Original Research BACKGROUND: Management of diabetes mellitus-induced erectile dysfunction (DMED) is challenging because of its insufficient responses to phosphodiesterase type 5 inhibitors. AIM: To compare the effects of ipidacrine, a reversible cholinesterase inhibitor, and sildenafil on DMED in a rat model of streptozotocin (STZ)-induced diabetes. METHODS: Erectile dysfunction (ED) caused by STZ-induced diabetes mellitus was modeled in adult male Wistar rats, which were randomized to 4 groups: untreated diabetic rats, sildenafil (5 mg/kg), ipidacrine (3.6 mg/kg) and ipidacrine (6.7 mg/kg). The test drug (ipidacrine), comparator (sildenafil) or control substance (1% starch solution) were administered orally for 5 days or 14 days. Erectile function was assessed by the change in the maximum intracavernous pressure (ICPmax) following cavernous nerve electrical stimulation. The mean arterial pressure (MAP) was recorded, and the ICPmax/MAP ratio was calculated. Sexual behavior, cholinesterase activity and blood testosterone level tests assessed. MAIN OUTCOME MEASURE: The quantitative value of ICPmax/MAP 14 days after the start of administration of the test drug and the comparison drug. RESULTS: Animals with STZ-induced diabetes mellitus showed a significant decrease in ICPmax and ICPmax/MAP ratio compared to the intact control group. When ipidacrine was administered to rats with DMED for 14 days, an increase in these indicators was noted. It was proved that ipidacrine at a dose of 6.7 mg/kg has noninferiority compared to sildenafil on the DMED model. Significant increase in ICPmax compared to STZ-control after electrostimulation of the cavernous nerve was recorded following administration of ipidacrine at a dose of 6.7 mg/kg (P < .05) and sildenafil at a dose 5 mg/kg (P < .05). Neither the test drug, nor the comparator were associated with increase in testosterone levels in blood; as well both drugs did not promote activation of sexual behavior. CLINICAL IMPLICATIONS: Ipidacrine may be considered as an effective therapy for DMED but needs to be verified in human investigations. STRENGTHS & LIMITATIONS: The role of ipidacrine, was firstly demonstrated in rats with DMED. However, the results were obtained in animal experiments, and will be further tested in the study of receptor interactions and the determination of cellular targets. CONCLUSION: This is the first study to show that administration of ipidacrine, the reversible cholinesterase inhibitor, improved erectile function in diabetic rats and these results may be beneficial in further studies using ipidacrine for treatment of DMED, particularly in non-responders to PDE5 inhibitors. Bykov V, Gushchina E, Morozov S, et al. Ipidacrine (Axamon), A Reversible Cholinesterase Inhibitor, Improves Erectile Function in Male Rats With Diabetes Mellitus-Induced Erectile Dysfunction. Sex Med 2022;10:100477. Elsevier 2022-01-08 /pmc/articles/PMC8847829/ /pubmed/35007992 http://dx.doi.org/10.1016/j.esxm.2021.100477 Text en Copyright © 2021 The Authors. Published by Elsevier Inc. on behalf of the International Society for Sexual Medicine. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research
Bykov, Vladimir
Gushchina, Evgenia
Morozov, Sergey
Zhuravskaya, Natalia
Kryshen, Kirill
Makarov, Valery
Matichin, Aleksandr
Zueva, Alena
Ipidacrine (Axamon), A Reversible Cholinesterase Inhibitor, Improves Erectile Function in Male Rats With Diabetes Mellitus-Induced Erectile Dysfunction
title Ipidacrine (Axamon), A Reversible Cholinesterase Inhibitor, Improves Erectile Function in Male Rats With Diabetes Mellitus-Induced Erectile Dysfunction
title_full Ipidacrine (Axamon), A Reversible Cholinesterase Inhibitor, Improves Erectile Function in Male Rats With Diabetes Mellitus-Induced Erectile Dysfunction
title_fullStr Ipidacrine (Axamon), A Reversible Cholinesterase Inhibitor, Improves Erectile Function in Male Rats With Diabetes Mellitus-Induced Erectile Dysfunction
title_full_unstemmed Ipidacrine (Axamon), A Reversible Cholinesterase Inhibitor, Improves Erectile Function in Male Rats With Diabetes Mellitus-Induced Erectile Dysfunction
title_short Ipidacrine (Axamon), A Reversible Cholinesterase Inhibitor, Improves Erectile Function in Male Rats With Diabetes Mellitus-Induced Erectile Dysfunction
title_sort ipidacrine (axamon), a reversible cholinesterase inhibitor, improves erectile function in male rats with diabetes mellitus-induced erectile dysfunction
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847829/
https://www.ncbi.nlm.nih.gov/pubmed/35007992
http://dx.doi.org/10.1016/j.esxm.2021.100477
work_keys_str_mv AT bykovvladimir ipidacrineaxamonareversiblecholinesteraseinhibitorimproveserectilefunctioninmaleratswithdiabetesmellitusinducederectiledysfunction
AT gushchinaevgenia ipidacrineaxamonareversiblecholinesteraseinhibitorimproveserectilefunctioninmaleratswithdiabetesmellitusinducederectiledysfunction
AT morozovsergey ipidacrineaxamonareversiblecholinesteraseinhibitorimproveserectilefunctioninmaleratswithdiabetesmellitusinducederectiledysfunction
AT zhuravskayanatalia ipidacrineaxamonareversiblecholinesteraseinhibitorimproveserectilefunctioninmaleratswithdiabetesmellitusinducederectiledysfunction
AT kryshenkirill ipidacrineaxamonareversiblecholinesteraseinhibitorimproveserectilefunctioninmaleratswithdiabetesmellitusinducederectiledysfunction
AT makarovvalery ipidacrineaxamonareversiblecholinesteraseinhibitorimproveserectilefunctioninmaleratswithdiabetesmellitusinducederectiledysfunction
AT matichinaleksandr ipidacrineaxamonareversiblecholinesteraseinhibitorimproveserectilefunctioninmaleratswithdiabetesmellitusinducederectiledysfunction
AT zuevaalena ipidacrineaxamonareversiblecholinesteraseinhibitorimproveserectilefunctioninmaleratswithdiabetesmellitusinducederectiledysfunction